Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
riGHt: Weekly lonapegsomatropin vs daily Genotropin in Japanese prepubertal children with growth hormone deficiency
jRCT2031200340Phase 3Active, not recruiting
- Sponsor
- Ascendis Pharma
- Start
- Jun 2021
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lonapegsomatropin in growth hormone deficiency (GHD) (4 arms), sponsored by Ascendis Pharma. Primary endpoint: Annualized height velocity at 52 weeks. Started Jun 2021; status: active, not recruiting.
02
Drugs
lonapegsomatropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on jRCT2031200340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200340.